Numerous studies have detected a greater likelihood of excess weight gain with specific
antiretrovirals (ARVs), particularly tenofovir alafenamide and integrase inhibitors, as …

Life expectancy of people living with HIV (PLWH) is now close to that of the HIV-uninfected
population. As a result, age-related comorbidities, including osteoporosis, are increasing in …

Importance Recent advances in treatment and prevention of HIV warrant updated
recommendations to guide optimal practice. Objective Based on a critical evaluation of new …

Background De novo steatosis is the main criteria for non-alcoholic fatty liver disease
(NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected patients. This …

Background Weight gain effects of individual antiretroviral drugs are not fully understood.
We investigated associations between a prespecified clinically significant increase (> 7%) in …

Rapid advances in the potency, safety, and availability of modern HIV antiretroviral therapy
(ART) have yielded a near-normal life expectancy for most people living with HIV (PLWH) …

The overall purpose of these guidelines is to provide guidance on best clinical practice for
antiretroviral therapy (ART) and management of adults living with human immunodeficiency …

Background: Recent clinical trials have shown weight gain associated with newer
antiretrovirals. It is unclear how the nucleoside reverse transcriptase inhibitor backbone …

Objective: The primary objective was to explore weight and BMI changes in people with HIV
(PWH) undergoing integrase strand transfer inhibitors (INSTI)-based regimens (vs. non …

Background: The timing and magnitude of antiretroviral therapy–associated weight change
attributions are unclear. Setting: HIV Outpatient Study participants. Methods: We analyzed …